CTLA4 and urothelial carcinoma: Some of the immunotherapies like immune checkpoint inhibitors (ICIs) target the proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and have completely changed the way that genitourinary malignancies like renal cell carcinoma and urothelial carcinoma are treated [12].